Development of DPP-4-resistant CXCL9-Fc and CXCL10-Fc chemokines for effective cancer immunotherapy.

Proc Natl Acad Sci U S A · 2025 · PMC12037015 · PMID 40238455

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

5 A shows a highly significant increase in CD8+ T cells at the tumor site following Q-CXCL10-Fc as compared to CXCL10-Fc administration.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.